New drug combo aims to shrink tough breast cancer tumors

NCT ID NCT07544056

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a new drug called BEBT-209 to standard chemotherapy can shrink tumors and help people with advanced triple-negative breast cancer live longer. About 446 women aged 18 to 75 will be randomly assigned to receive either BEBT-209 plus two chemo drugs or chemo alone. Researchers will monitor tumor response, survival, side effects, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••